N-(4-aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide hydrochloride | 953090-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide hydrochloride
• 英文别名: 3-Ethynyl-5-fluoro-4-methansulfonylaminobenzylamine hydrochloride；N-[4-(aminomethyl)-2-ethynyl-6-fluorophenyl]methanesulfonamide;hydrochloride
• CAS: 953090-75-0
• 化学式: C₁₀H₁₁FN₂O₂S*ClH
• 分子量: 278.735
• InChiKey: LJGZUNSGNOERLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.06
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(4-aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide hydrochloride 、 3-(4-叔丁基苯)-丙酸 在 N-甲基吗啉 、 三乙胺 、 4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 以90%的产率得到3-(4-tert-butylphenyl)-N-[3-acetylenyl-5-fluoro-4-(methylsulfonamido)benzyl]propanamide
  参考文献：
  名称：

  Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists

  摘要：

  Structural optimization of multiple H-bonding region and structure-activity relationship of diarylalkyl amides/thioamides as novel TRPV1 antagonists are described. In particular, we identified amide 34o and thioamides 35o and 35r, of which antagonistic activities were highly enhanced by an incorporation of cyano or vinyl-substituent to the multiple H-bonding region. They exhibited potent Ca-45(2+) uptake inhibitions in rat DRG neuron with IC(50)s of 25, 32 and 28 nM, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.043
• 作为产物：
  描述：

  tert-butyl 3-ethynyl-5-fluoro-4-(methylsulfonamido)benzylcarbamate 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 以100%的产率得到N-(4-aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide hydrochloride
  参考文献：
  名称：

  Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists

  摘要：

  Structural optimization of multiple H-bonding region and structure-activity relationship of diarylalkyl amides/thioamides as novel TRPV1 antagonists are described. In particular, we identified amide 34o and thioamides 35o and 35r, of which antagonistic activities were highly enhanced by an incorporation of cyano or vinyl-substituent to the multiple H-bonding region. They exhibited potent Ca-45(2+) uptake inhibitions in rat DRG neuron with IC(50)s of 25, 32 and 28 nM, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.043

文献信息

• Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1882687A1

  公开（公告）日：2008-01-30

  This present invention relates to novel compounds, of the formula (I), isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1;VR1;TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis and pancreatitis.

  这项发明涉及新化合物，其化学式为(I)，其异构体或其药学上可接受的盐作为辣椒素受体（辣椒素受体1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病的药物组合物，如疼痛、关节炎炎症性疾病、神经病、艾滋病相关神经病、神经损伤、神经退行性疾病、中风、包括尿失禁、膀胱过敏、膀胱炎、胃十二指肠溃疡、肠易激综合征（IBS）和炎症性肠病（IBD）、粪便紧急情况、胃食管反流病（GERD）、克罗恩病、哮喘、慢性阻塞性肺病、咳嗽、神经症/过敏/炎症性皮肤病、牛皮癣、瘙痒症、疹痒症、皮肤、眼睛或粘膜刺激、听觉过敏、耳鸣、前庭过敏、阵发性眩晕、心脏疾病如心肌缺血、与头发生长有关的疾病如脱发、脱发、鼻炎和胰腺炎。
• NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：KIM Sun-Young

  公开号：US20080312234A1

  公开（公告）日：2008-12-18

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本发明涉及一种新型化合物、其异构体或其药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1；VR1；TRPV1）拮抗剂；以及包含该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病的药物组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合症、排便紧迫、呼吸道疾病、皮肤、眼睛或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳疾病、心脏疾病等。
• Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：US07858621B2

  公开（公告）日：2010-12-28

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本发明涉及新型化合物、其异构体或其药学上可接受的盐，作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及含有该化合物的制药组合物。本发明提供了一种用于预防或治疗疾病的制药组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合征、大便紧迫、呼吸系统疾病、皮肤、眼睛或黏膜刺激、胃十二指肠溃疡、炎症性疾病、耳病、心脏病等。
• Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1857440A1

  公开（公告）日：2007-11-21

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

  本发明涉及作为类香草素受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂的新型化合物、其异构体或其药学上可接受的盐；以及含有这些化合物的药物组合物。 本发明提供了一种药物组合物，用于预防或治疗疼痛、偏头痛、关节痛、神经痛、神经病变、神经损伤、皮肤病、膀胱过敏、肠易激综合征、便急、呼吸系统疾病、皮肤、眼睛或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳病和心脏病等疾病。
• WO2007/120012
  申请人：——

  公开号：——

  公开（公告）日：——